These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 31466933)

  • 1. Recombinant Adenovirus Expressing a Soluble Fusion Protein PD-1/CD137L Subverts the Suppression of CD8
    Zhang Y; Zhang H; Wei M; Mou T; Shi T; Ma Y; Cai X; Li Y; Dong J; Wei J
    Mol Ther; 2019 Nov; 27(11):1906-1918. PubMed ID: 31466933
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant adenovirus expressing the fusion protein PD1PVR improves CD8
    Zhang H; Zhang Y; Dong J; Zuo S; Meng G; Wu J; Wei J
    Cell Oncol (Dordr); 2021 Dec; 44(6):1243-1255. PubMed ID: 34491549
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced antitumor efficacy of a novel fiber chimeric oncolytic adenovirus expressing p53 on hepatocellular carcinoma.
    Chen W; Wu Y; Liu W; Wang G; Wang X; Yang Y; Chen W; Tai Y; Lu M; Qian Q; Zhang Q; Chen G
    Cancer Lett; 2011 Aug; 307(1):93-103. PubMed ID: 21504839
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oncolytic measles virus enhances antitumour responses of adoptive CD8
    Chen A; Zhang Y; Meng G; Jiang D; Zhang H; Zheng M; Xia M; Jiang A; Wu J; Beltinger C; Wei J
    Sci Rep; 2017 Jul; 7(1):5170. PubMed ID: 28701757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An Oncolytic Adenovirus Targeting Transforming Growth Factor β Inhibits Protumorigenic Signals and Produces Immune Activation: A Novel Approach to Enhance Anti-PD-1 and Anti-CTLA-4 Therapy.
    Yang Y; Xu W; Peng D; Wang H; Zhang X; Wang H; Xiao F; Zhu Y; Ji Y; Gulukota K; Helseth DL; Mangold KA; Sullivan M; Kaul K; Wang E; Prabhakar BS; Li J; Wu X; Wang L; Seth P
    Hum Gene Ther; 2019 Sep; 30(9):1117-1132. PubMed ID: 31126191
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted Hsp70 expression combined with CIK-activated immune reconstruction synergistically exerts antitumor efficacy in patient-derived hepatocellular carcinoma xenograft mouse models.
    Hu H; Qiu Y; Guo M; Huang Y; Fang L; Peng Z; Ji W; Xu Y; Shen S; Yan Y; Huang X; Zheng J; Su C
    Oncotarget; 2015 Jan; 6(2):1079-89. PubMed ID: 25473902
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oncolytic Adenovirus Expressing Monoclonal Antibody Trastuzumab for Treatment of HER2-Positive Cancer.
    Liikanen I; Tähtinen S; Guse K; Gutmann T; Savola P; Oksanen M; Kanerva A; Hemminki A
    Mol Cancer Ther; 2016 Sep; 15(9):2259-69. PubMed ID: 27458139
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combining IL-10 and Oncolytic Adenovirus Demonstrates Enhanced Antitumor Efficacy Through CD8
    Chen D; Huang L; Zhou H; Zhang Y
    Front Immunol; 2021; 12():615089. PubMed ID: 33717103
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An Artificially Designed Interfering lncRNA Expressed by Oncolytic Adenovirus Competitively Consumes OncomiRs to Exert Antitumor Efficacy in Hepatocellular Carcinoma.
    Li X; Su Y; Sun B; Ji W; Peng Z; Xu Y; Wu M; Su C
    Mol Cancer Ther; 2016 Jul; 15(7):1436-51. PubMed ID: 27196772
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetically engineered recombinant adenovirus expressing interleukin‑2 for hepatocellular carcinoma therapy.
    Sun Y; Wu H; Chen G; Huang X; Shan Y; Shi H; Zhang Q; Zheng Y
    Mol Med Rep; 2018 Jan; 17(1):300-306. PubMed ID: 29115604
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The spatial and single-cell analysis reveals remodeled immune microenvironment induced by synthetic oncolytic adenovirus treatment.
    Liu G; Hu Q; Peng S; Ning H; Mai J; Chen X; Tao M; Liu Q; Huang H; Jiang Y; Ding Y; Zhang X; Gu J; Xie Z
    Cancer Lett; 2024 Jan; 581():216485. PubMed ID: 38008394
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Chen K; Wu Z; Zhao H; Wang Y; Ge Y; Wang D; Li Z; An C; Liu Y; Wang F; Bi X; Wang H; Cai J; Ma C; Qu C
    Cancer Immunol Res; 2020 Jan; 8(1):81-93. PubMed ID: 31666238
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel oncolytic adenovirus targeting Wnt signaling effectively inhibits cancer-stem like cell growth via metastasis, apoptosis and autophagy in HCC models.
    Zhang J; Lai W; Li Q; Yu Y; Jin J; Guo W; Zhou X; Liu X; Wang Y
    Biochem Biophys Res Commun; 2017 Sep; 491(2):469-477. PubMed ID: 28698142
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An autologous in situ tumor vaccination approach for hepatocellular carcinoma. 2. Tumor-specific immunity and cure after radio-inducible suicide gene therapy and systemic CD40-ligand and Flt3-ligand gene therapy in an orthotopic tumor model.
    Kawashita Y; Deb NJ; Garg MK; Kabarriti R; Fan Z; Alfieri AA; Roy-Chowdhury J; Guha C
    Radiat Res; 2014 Aug; 182(2):201-10. PubMed ID: 24992166
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
    Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
    Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel Golgi protein (GOLPH2)-regulated oncolytic adenovirus exhibits potent antitumor efficacy in hepatocellular carcinoma.
    Wang Y; Liu T; Huang P; Zhao H; Zhang R; Ma B; Chen K; Huang F; Zhou X; Cui C; Liu X
    Oncotarget; 2015 May; 6(15):13564-78. PubMed ID: 25980438
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-tumor activity of a miR-199-dependent oncolytic adenovirus.
    Callegari E; Elamin BK; D'Abundo L; Falzoni S; Donvito G; Moshiri F; Milazzo M; Altavilla G; Giacomelli L; Fornari F; Hemminki A; Di Virgilio F; Gramantieri L; Negrini M; Sabbioni S
    PLoS One; 2013; 8(9):e73964. PubMed ID: 24069256
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An Oncolytic Adenovirus Encoding Decorin and Granulocyte Macrophage Colony Stimulating Factor Inhibits Tumor Growth in a Colorectal Tumor Model by Targeting Pro-Tumorigenic Signals and via Immune Activation.
    Liu Z; Yang Y; Zhang X; Wang H; Xu W; Wang H; Xiao F; Bai Z; Yao H; Ma X; Jin L; Wu C; Seth P; Zhang Z; Wang L
    Hum Gene Ther; 2017 Aug; 28(8):667-680. PubMed ID: 28530155
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TOX promotes the exhaustion of antitumor CD8
    Wang X; He Q; Shen H; Xia A; Tian W; Yu W; Sun B
    J Hepatol; 2019 Oct; 71(4):731-741. PubMed ID: 31173813
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Augmenting the antitumor effect of TRAIL by SOCS3 with double-regulated replicating oncolytic adenovirus in hepatocellular carcinoma.
    Wei RC; Cao X; Gui JH; Zhou XM; Zhong D; Yan QL; Huang WD; Qian QJ; Zhao FL; Liu XY
    Hum Gene Ther; 2011 Sep; 22(9):1109-19. PubMed ID: 21361790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.